Joseph Schwartz
Stock Analyst at Leerink Partners
(2.52)
# 2,101
Out of 4,814 analysts
143
Total ratings
30.23%
Success rate
16.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $8.36 | +234.93% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $14.92 | +168.10% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.33 | +4,165.69% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $3.06 | +30.72% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.25 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $2.56 | +369.67% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $2.31 | +247.07% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $2.04 | +194.12% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.12 | +1,526.02% | 5 | Mar 14, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.03 | -2.91% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $3.52 | +70.45% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $47.45 | +1.16% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $14.00 | +28.57% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $12.09 | +65.43% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $28.32 | +20.06% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $59.12 | +119.89% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $53.79 | +197.45% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $160.53 | +1.54% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $0.84 | +1,083.85% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.33 | +2,381.20% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $7.76 | +54.64% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $35.64 | +203.03% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $72.47 | -31.01% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $30.40 | +28.29% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.06 | +277.36% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $13.41 | +123.80% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $26.67 | +87.48% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $46.32 | -35.23% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $13.00 | +330.77% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.83 | +105.13% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.15 | +948.03% | 2 | Sep 26, 2017 |
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $8.36
Upside: +234.93%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $14.92
Upside: +168.10%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.33
Upside: +4,165.69%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $3.06
Upside: +30.72%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.25
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $2.56
Upside: +369.67%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.31
Upside: +247.07%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $2.04
Upside: +194.12%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.12
Upside: +1,526.02%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.03
Upside: -2.91%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $3.52
Upside: +70.45%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $47.45
Upside: +1.16%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $14.00
Upside: +28.57%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $12.09
Upside: +65.43%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $28.32
Upside: +20.06%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $59.12
Upside: +119.89%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $53.79
Upside: +197.45%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $160.53
Upside: +1.54%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $0.84
Upside: +1,083.85%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.33
Upside: +2,381.20%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $7.76
Upside: +54.64%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $35.64
Upside: +203.03%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $72.47
Upside: -31.01%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $30.40
Upside: +28.29%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.06
Upside: +277.36%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $13.41
Upside: +123.80%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $26.67
Upside: +87.48%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $46.32
Upside: -35.23%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $13.00
Upside: +330.77%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $6.83
Upside: +105.13%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.15
Upside: +948.03%